Artículos del autor

solaci

Day 2

PARTNER 2: Edwards SAPIEN XT is even better. Results for PARTNER II, cohort B.

In the PARTNER 1 study, patients with inoperable severe aortic stenosis treated with an aortic valve prosthesis...
solaci -
Day 2

DKCRUSH-III: Crushing versus Culotte technique for left main coronary artery

Angioplasty of the unprotected distal left main coronary artery with 2 stents presents the less favorable results...
solaci -
Day 2

STREAM trial: It is time to check out facilitated angioplasty?

It is not clear so far whether pre-hospital fibrinolysis with early angiography could provide a clinical outcome...
solaci -
Day 1

THRIVE: Niacin/laropiprant extended release showed no significant cardiovascular benefit.

The THRIVE study, (also known as HPS2-THRIVE), was a multicenter clinical trial designed to test the hypothesis...
solaci -
Day 1

PREVAIL: LAA occlusion versus anticoagulation with warfarin to prevent stroke in patients with non-valvular atrial fibrillation.

An hour before the presentation of the PREVAIL study, the ACC announced the cancellation of the release...
solaci -
Day 1

TCT Session

Alan Wilson and Szeto Zajarias show that vascular complications of the trans-femoral path remain an important factor...
solaci -
SOLACI Session

Mitral valve repair: were we are and what we would expect for LATAM in the near future

Magnus Seergren2013-08-21
solaci -
SOLACI Session

Value of New Devices for Improving Outcomes

Eberhard Grube2013-05-21
solaci -